Chiesi Global Rare Diseases and Protalix BioTherapeutics Seek Re-examination from the EMA for the Negative Opinion for Elfabrio (pegunigalsidase alfa) Alternative Dos…

Every two weeks remains approved as a dosing regimen of Elfabrio in the EU --PARMA, Italy and CARMIEL, Israel, Nov. 03, 2025 ...

Bausch + Lomb to Hold Investor Day on Nov. 13

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, will hold an investor day on Thursday, Nov. 13, 2025, at the New ...
The Manila Times

Freshpet, Inc. Reports Third Quarter 2025 Financial Results

BEDMINSTER, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Freshpet, Inc. ("Freshpet” or the "Company”) (Nasdaq: FRPT) today reported financial results for its third quarter and nine months ended September ...